5748-34-5

Basic information

• Product Name: (4-Chloro-6-methyl-pyrimidin-2-yl)-isopropyl-amine
• Synonyms: (4-Chloro-6-methyl-pyrimidin-2-yl)-isopropyl-amine;4-Chloro-2-(isopropylamino)-6-methylpyrimidine;4-Chloro-6-methyl-N-(1-methylethyl)-2-pyrimidinamine
• CAS NO: 5748-34-5
• Molecular Formula: C₈H₁₂ClN₃
• Molecular Weight: 186
• Mol File: 5748-34-5.mol

Chemical Properties

• Boiling Point: 290℃
• Flash Point: 129℃
• Appearance: /
• Density: 1.182
• Vapor Pressure: 5.64E-21mmHg at 25°C
• Refractive Index: 1.72
• CAS DataBase Reference: (4-Chloro-6-methyl-pyrimidin-2-yl)-isopropyl-amine(CAS DataBase Reference)
• NIST Chemistry Reference: (4-Chloro-6-methyl-pyrimidin-2-yl)-isopropyl-amine(5748-34-5)
• EPA Substance Registry System: (4-Chloro-6-methyl-pyrimidin-2-yl)-isopropyl-amine(5748-34-5)

Safety Data

• Hazardous Substances Data: 5748-34-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(4-Chloro-6-methyl-pyrimidin-2-yl)-isopropyl-amine is used as an intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of new drugs and therapeutic agents.
Used in Crop Protection Industry:
In agriculture, (4-Chloro-6-methyl-pyrimidin-2-yl)-isopropyl-amine is used as a component in the creation of crop protection agents, helping to enhance crop yield and protect plants from pests and diseases.
Used in Chemical Synthesis:
(4-Chloro-6-methyl-pyrimidin-2-yl)-isopropyl-amine serves as a building block in the synthesis of other organic compounds, playing a crucial role in the development of new chemical products and materials.

InChI:InChI=1/C28H15N3O6/c32-25(16-5-3-8-20(13-16)31(35)36)17-11-12-21-22(15-17)28(34)30(27(21)33)19-7-4-6-18(14-19)26-29-23-9-1-2-10-24(23)37-26/h1-15H

Upstream product

• 5424-21-5 2,4-dichloro-6-methylpyrimidine 
• 75-31-0 isopropylamine 

Relevant articles and documents

ANTIVIRAL COMPOUNDS

The invention is provides novel antiviral compounds, as well as derivatives thereof. The compounds of the invention are preferably formulated as pharmaceuticals. The invention provides the compounds for use in the prevention and treatment of infectious diseases, in particular viral diseases. In some aspects the invention is based on the antiviral activity of the provided compounds against the Chikungunya virus, and hence, their application in the treatment or prevention of any physiological manifestation of such viral infection.

Identification of 2-(4-(Phenylsulfonyl)piperazine-1-yl)pyrimidine Analogues as Novel Inhibitors of Chikungunya Virus

The chikungunya virus (CHIKV) is a mosquito-transmitted alphavirus, and it is the causative agent of chikungunya fever (CHIKF). Although it has re-emerged as an epidemic threat, so far there are neither vaccines nor pharmacotherapy available to prevent or treat an infection. Herein, we describe the synthesis and structure-activity relationship studies of a class of novel small molecule inhibitors against CHIKV and the discovery of a new potent inhibitor (compound 6a). The starting point of the optimization process was N-ethyl-6-methyl-2-(4-(4-fluorophenylsulfonyl)piperazine-1-yl)pyrimidine-4-amine (1) with an EC50 of 8.68 μM, a CC50 of 122 μM, and therefore a resulting selectivity index (SI) of 14.2. The optimized compound 6a, however, displays a much lower micromolar antiviral activity (EC50 value of 3.95 μM), considerably better cytotoxic liability (CC50 value of 260 μM) and consequently an improved SI of greater than 61. Therefore, we report the identification of a promising novel compound class that has the potential for further development of antiviral drugs against the CHIKV.

Discovery of a Novel Mycobacterial F-ATP Synthase Inhibitor and its Potency in Combination with Diarylquinolines

The F1FO-ATP synthase is required for growth and viability of Mycobacterium tuberculosis and is a validated clinical target. A mycobacterium-specific loop of the enzyme's rotary γ subunit plays a role in the coupling of ATP synthesis within the enzyme complex. We report the discovery of a novel antimycobacterial, termed GaMF1, that targets this γ subunit loop. Biochemical and NMR studies show that GaMF1 inhibits ATP synthase activity by binding to the loop. GaMF1 is bactericidal and is active against multidrug- as well as bedaquiline-resistant strains. Chemistry efforts on the scaffold revealed a dynamic structure activity relationship and delivered analogues with nanomolar potencies. Combining GaMF1 with bedaquiline or novel diarylquinoline analogues showed potentiation without inducing genotoxicity or phenotypic changes in a human embryonic stem cell reporter assay. These results suggest that GaMF1 presents an attractive lead for the discovery of a novel class of anti-tuberculosis F-ATP synthase inhibitors.